GlassScriptPhysician profile
Nehal Masood
NPI 1407291230
$546.72
in general payments reported to CMS, 2019-2025
24 companies · $81.17 in 2025
The $81.17 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.57 · 2020: $15.13 · 2021: $34.94 · 2022: $113 · 2023: $14.30 · 2024: $205 · 2025: $81.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $116.02 | 2024 | |
| Pfizer INC. | $102.34 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $101.48 | 2019-2022 | |
| Genzyme Corporation | $81.17 | 2025 | |
| Celgene Corporation | $63.17 | 2022-2023 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $45.46 | 2021-2022 | |
| Gilead Sciences, INC. | $24.81 | 2019 | |
| Astellas Pharma US INC | $12.27 | 2019 |
16 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nehal Masood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.